Ajanta Pharma Limited (NSE: AJANTPHARM) and RUBICON RESEARCH LIMITED (NSE: RUBICON) are both listed in the Pharmaceuticals industry. Ajanta Pharma has a market capitalisation of ₹41,474 Cr and RUBICON RESEARCH ₹28,526 Cr, as of 16 Nov 2026. Their P/E ratios are 39.4 and 112.3 respectively. Return on equity is 25.39% for Ajanta Pharma and 19.14% for RUBICON RESEARCH. Over one year, Ajanta Pharma's share price is up 27.8% and RUBICON RESEARCH's is up 162.7%.
| Metric | Ajanta Pharma | RUBICON RESEARCH |
|---|---|---|
| NSE Symbol | AJANTPHARM | RUBICON |
| BSE Code | 532331 | 544578 |
| Share Price | ₹3,279.00 | ₹1,675.00 |
| Market Cap | ₹41,474 Cr | ₹28,526 Cr |
| P/E Ratio | 39.4 | 112.3 |
| Return on Equity | 25.39% | 19.14% |
| Return on Assets | 14.85% | 11.74% |
| Dividend Yield | 1.92% | 0.09% |
| Beta (1Y) | 0.19 | 0.11 |
| 1-Year Price Change | +27.8% | +162.7% |
| 3-Month Price Change | -9.1% | +3.5% |
| 52-Week Range | ₹2,445.80 – ₹3,796.00 | ₹615.20 – ₹1,899.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹1,794 Cr | ₹576 Cr |
| Quarterly Net Profit | ₹388 Cr | ₹90 Cr |
| Net Margin | 21.6% | 15.7% |
| EPS (Basic, Quarter) | ₹31.07 | ₹5.47 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 19…
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabol…
Ajanta Pharma has a market capitalisation of ₹41,474 Cr, against ₹28,526 Cr for RUBICON RESEARCH as of 16 Nov 2026, about 1.5 times the size by market cap.
Ajanta Pharma has a P/E of 39.4 and RUBICON RESEARCH a P/E of 112.3 as of 16 Nov 2026.
Ajanta Pharma has a return on equity of 25.39% and RUBICON RESEARCH 19.14%.
Ajanta Pharma's share price is up 27.8% over one year and RUBICON RESEARCH's is up 162.7%.
Ajanta Pharma reported revenue of ₹1,794 Cr and net profit of ₹388 Cr for Q2 FY27. RUBICON RESEARCH reported revenue of ₹576 Cr and net profit of ₹90 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.